Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Peter MacCallum Cancer Centre

Melbourne, Victoria 3000, AustraliaPeter MacCallum Cancer Centre

175running trials
53closed trials

Part of

Peter MacCallum Cancer Centre

Trial registries list Peter MacCallum Cancer Centre under 44 sites and names; the figures below count all of them.

316trials across all its sites
231of them running
44registry sites and names
23,708publications (OpenAlex)

Type (ROR): Healthcare
Website: petermac.org
Publishes most on: Prostate cancer
Lung cancer
Melanoma
Ovarian cancer
Multiple myeloma
Sarcoma

See all 316 trials at Peter MacCallum Cancer Centre

Institution data from ROR and OpenAlex, trial counts from the trial registries.

The trials here

What the 229 trials at this site are about, from their registry records.

Conditions: Lung cancer40 trials
Prostate cancer39 trials
Childhood cancers29 trials
Colorectal cancer27 trials
Pancreatic cancer17 trials
Melanoma16 trials
Head and neck cancer15 trials
Multiple myeloma15 trials
Chronic lymphocytic leukaemia14 trials
Metastatic breast cancer14 trials
Gastric and oesophageal cancer10 trials
Sarcoma10 trials
and 24 more
Phase: Phase 366 trials
Phase 153 trials
Phase 250 trials
Phase 1/227 trials
Phase 2/312 trials
Phase 43 trials
Status: Recruiting82 trials
Active, not recruiting81 trials
Completed39 trials
Terminated13 trials
Not yet recruiting10 trials
Enrolling by invitation2 trials
Suspended1 trial
Withdrawn1 trial
Lead sponsor: Peter MacCallum Cancer Centre, Australia28 trials
Janssen Research & Development, LLC20 trials
Hoffmann-La Roche14 trials
Pfizer13 trials
Amgen10 trials
and 88 more

Running trials

Not yet recruiting
A Master Trial Assessing the Technical Feasibility of First-In-Human Real-Time Image Guided Radiation Therapy Methods
NCT06708221· University of Sydney· Source
Contact: Nick Hardcastle
Not yet recruiting
Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma
NCT07840001· Phase 2· Peter MacCallum Cancer Centre, Australia· Source
Contact: PCCTU MoncA
Recruiting
Evaluation of XYA02 in Patients With Advanced Solid Tumors
NCT07670312· Phase 1/2· XYone Therapeutics, Inc· Source
Contact: Tiffany Sepp
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200· Phase 3· Incyte Corporation· Source
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma
NCT07565285· Phase 2· Primmune Therapeutics, Inc.· Source
Contact: Gunjan Mody
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Hoffmann-La Roche· Source
Recruiting
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
NCT07527858· Phase 2· Gilead Sciences· Source
Recruiting
Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease
NCT07541391· Phase 1· Peter MacCallum Cancer Centre, Australia· Source
Contact: Mark Dowling, PhD, MBBS
Recruiting
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
NCT07297979· Phase 1· Amgen· Source
Not yet recruiting
Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)
NCT07527819· Peter MacCallum Cancer Centre, Australia· Source
Contact: Dr Wanda Cui
Recruiting
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT07455851· Phase 1/2· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
NCT07491497· Phase 1/2· TRIANA Biomedicines, Inc.· Source
Contact: Ben Solomon, MD (principal investigator)
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· Phase 3· Incyte Corporation· Source
Recruiting
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
NCT07258407· Phase 1/2· T.O.A.D. Oncology SA· Source
Contact: TOAD Clinical Operations
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Eli Lilly and Company· Source
Contact: Julia Dixon-Douglas (principal investigator)
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· Phase 3· Pfizer· Source
Recruiting
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07244341· Phase 1· Daiichi Sankyo· Source
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Describe the Effect of Photobiomodulation (Low Level Laser Therapy) in Reducing the Severity and Incidence of Oral Mucositis (Oral Ulceration) in Oral Cancer Patients Undergoing Radiation Treatment
NCT07387978· Peter MacCallum Cancer Centre, Australia· Source
Contact: Sophie Beaumont, Bachelor of Dental surgery
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751· Phase 3· BioNTech SE· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· Phase 3· Hoffmann-La Roche· Source
Recruiting
PRIORITY-CONNECT 2 Trial
NCT06976710· Surgical Outcomes Research Centre (SOuRCe)· Source
Contact: Bernard Riedel
Active, not recruiting
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
NCT07140900· Phase 1· Amgen· Source
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Peter Savas, Site 0274
Recruiting
IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma
NCT07138222· Peter MacCallum Cancer Centre, Australia· Source
Contact: Dr Wanda Cui, BMEDSCI, MBBS, FRACP
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· BeOne Medicines· Source
Contact: Study Director
Not yet recruiting
Home-Based Photo-Biomodulation for Management of Lymphoedema and Radiation Fibrosis in Patients After Head and Neck Cancer: A Single-Arm Feasibility Trial
NCT07139782· Peter MacCallum Cancer Centre, Australia· Source
Contact: Megan Howard
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
NCT07147348· Phase 1/2· BioNTech SE· Source
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318· Phase 3· Takeda· Source
Contact: Isaac Goncalves (principal investigator)
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113· Phase 1· Amgen· Source
Recruiting
A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
NCT06383338· Phase 1· Murdoch Childrens Research Institute· Source
Contact: Marliese Alexander, Doctor of Philosophy
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755· Phase 2/3· Exelixis· Source
Contact: Exelixis Clinical Trials
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109· Phase 3· Nuvalent Inc.· Source
Contact: Benjamin Solomon, MBBS, Ph.D. (principal investigator)
Recruiting
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
NCT07075185· Phase 1· Kelonia Therapeutics, Inc.· Source
Contact: Hannah Pahl
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568· Phase 3· BioNTech SE· Source
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649· Phase 4· Eli Lilly and Company· Source
Contact: John Seymour (principal investigator)
Recruiting
Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
NCT06812715· Phase 2· Peter MacCallum Cancer Centre, Australia· Source
Contact: John F Seymour
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236· Phase 1/2· BioNTech SE· Source
Recruiting
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
NCT06510699· Phase 2· The University of Queensland· Source
Contact: Monica Slavin, MBBS, FRACP, MD, FAAHMS, FECMM
Recruiting
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079· Phase 1· TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)· Source
Contact: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Active, not recruiting
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT06651229· Phase 1· Janssen Research & Development, LLC· Source
Active, not recruiting
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
NCT06840483· Phase 2· BicycleTx Limited· Source
Recruiting
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235· Phase 3· Takeda· Source
Contact: Isaac Goncalves (principal investigator)
Recruiting
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT06756932· Phase 1· BeOne Medicines· Source
Contact: Study Director

Showing 50 of 175.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer21 recruiting
Childhood cancers14 recruiting
Colorectal cancer14 recruiting
Prostate cancer13 recruiting
Pancreatic cancer9 recruiting
Head and neck cancer8 recruiting
Metastatic breast cancer8 recruiting
Melanoma6 recruiting
Chronic lymphocytic leukaemia5 recruiting
Sarcoma5 recruiting
Triple-negative breast cancer5 recruiting
Multiple myeloma4 recruiting
Neuroendocrine tumours4 recruiting
Ovarian cancer4 recruiting
Endometrial cancer3 recruiting
Kidney cancer3 recruiting
Liver and biliary tract cancer3 recruiting
Gastric and oesophageal cancer2 recruiting
Glioblastoma2 recruiting
Immune thrombocytopenia (ITP)2 recruiting
Acute myeloid leukaemia1 recruiting
Amyloidosis1 recruiting
Bladder cancer1 recruiting
Chronic myeloid leukaemia1 recruiting
Diffuse large B-cell lymphoma1 recruiting
Follicular lymphoma1 recruiting
Hodgkin lymphoma1 recruiting
Mantle cell lymphoma1 recruiting
Myeloproliferative neoplasms1 recruiting
Thyroid cancer1 recruiting

Closed trials

Withdrawn
Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer
NCT07090369· Phase 1· Peter MacCallum Cancer Centre, Australia· Source
Recruiting
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
NCT06876662· Phase 4· Eli Lilly and Company· Source
Terminated
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
NCT06585488· Phase 1· BeOne Medicines· Source
Terminated
A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
NCT06194877· Phase 1· MapKure, LLC· Source
Completed
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
NCT06058793· Phase 3· Boehringer Ingelheim· Source
Recruiting
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
NCT05876312· Phase 1/2· ADARx Pharmaceuticals, Inc.· Source
Contact: Stephanie Leyva
Terminated
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
NCT05743036· Phase 1· K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc· Source
Completed
Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
NCT05546476· Phase 2· Pfizer· Source
Terminated
Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer
NCT05425862· Phase 1· Peter MacCallum Cancer Centre, Australia· Source
Terminated
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
NCT05079230· Phase 3· Gilead Sciences· Source
Completed
A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma
NCT05187624· Phase 1· Hoffmann-La Roche· Source
Completed
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
NCT05218499· Phase 2/3· Boehringer Ingelheim· Source
Terminated
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT05252390· Phase 1· Nuvation Bio Inc.· Source
Completed
A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
NCT04984356· Phase 1· Allotera Therapeutics· Source
Completed
Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
NCT04925648· Phase 2· St Vincent's Hospital, Sydney· Source
Completed
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
NCT05095519· Phase 2· Peter MacCallum Cancer Centre, Australia· Source
Completed
A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
NCT04702737· Phase 1· Amgen· Source
Completed
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
NCT04744831· Phase 2· Daiichi Sankyo· Source
Completed
A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
NCT04438304· Phase 2· Clarity Pharmaceuticals Ltd· Source
Completed
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
NCT04657224· Phase 1· Janssen Research & Development, LLC· Source
Completed
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
NCT04334759· Phase 3· PrECOG, LLC.· Source
Terminated
Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
NCT04093362· Phase 3· Taiho Oncology, Inc.· Source
Completed
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
NCT04670679· Phase 1· Erasca, Inc.· Source
Terminated
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
NCT04383210· Phase 2· Elevation Oncology· Source
Completed
A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer
NCT04468607· Phase 1· Genentech, Inc.· Source
Terminated
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Terminated
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial
NCT04316013· Phase 3· Peter MacCallum Cancer Centre, Australia· Source
Completed
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
NCT04303780· Phase 3· Amgen· Source
Completed
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
NCT04294810· Phase 3· Hoffmann-La Roche· Source
Completed
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
NCT04172675· Phase 2· Janssen Research & Development, LLC· Source
Completed
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT04215978· Phase 1· BeiGene· Source
Completed
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
NCT04090710· Phase 2· Ontario Clinical Oncology Group (OCOG)· Source
Terminated
A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04244656· Phase 1· CRISPR Therapeutics AG· Source
Recruiting
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NCT05999994· Phase 2· Eli Lilly and Company· Source
Completed
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
NCT04068181· Phase 2· Amgen· Source
Terminated
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
NCT04171141· Phase 1· Pfizer· Source
Completed
Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer
NCT03900884· Phase 1· Peter MacCallum Cancer Centre, Australia· Source
Completed
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT03900598· Phase 1· Janssen Research & Development, LLC· Source
Completed
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
NCT03740529· Phase 1/2· Loxo Oncology, Inc.· Source
Completed
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
NCT03815058· Phase 2· Genentech, Inc.· Source
Completed
A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma
NCT03331731· Phase 2· Peter MacCallum Cancer Centre, Australia· Source
Completed
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
NCT03523585· Phase 3· Daiichi Sankyo· Source
Completed
BEACON - ABC in Recurrent Platinum Resistant HGSOC
NCT03363867· Phase 2· Peter MacCallum Cancer Centre, Australia· Source
Completed
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
NCT03517449· Phase 3· Eisai Inc.· Source
Completed
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
NCT03467373· Phase 1· Hoffmann-La Roche· Source
Terminated
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
NCT03281369· Phase 1/2· Hoffmann-La Roche· Source
Completed
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
NCT02923934· Phase 2· Olivia Newton-John Cancer Research Institute· Source
Completed
Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
NCT02662062· Phase 2· Australian and New Zealand Urogenital and Prostate Cancer Trials Group· Source
Completed
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
NCT03072238· Phase 3· Hoffmann-La Roche· Source
Completed
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
NCT02908672· Phase 3· Hoffmann-La Roche· Source

Showing 50 of 53.

Site data: ClinicalTrials.govUpdated 13 Nov 2026

Report an error